Sara Fuentelsaz-Romero1, Andrea Cuervo2, Lizbeth Estrada-Capetillo1, Raquel Celis2, Raquel García-Campos1, Julio Ramírez2, Sergi Sastre3, Rafael Samaniego4, Amaya Puig-Kröger1, Juan D Cañete2. 1. Unidad de Inmuno-Metabolismo e Inflamación, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital General Universitario Gregorio Marañón, Madrid, Spain. 2. Unidad de Artritis, Servicio de Reumatología, Hospital Clínic and IDIBAPS, Barcelona, Spain. 3. Sección de Artroscopia, Servicio de Cirugía Ortopédica y Traumatología, Hospital Clínic, Barcelona, Spain. 4. Unidad de Microscopía Confocal, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Abstract
Background and Aims: GM-CSF-dependent macrophage polarization has been demonstrated in rheumatoid arthritis (RA). Our aim was to seek diagnostic/prognostic biomarkers for undifferentiated arthritis (UA) by analyzing GM-CSF expression and source, macrophage polarization and density in joints of patients with UA evolving to RA or PsA compared with established RA or PsA, respectively. Methods: Synovial tissue (ST) from patients with UA evolving to RA (UA>RA, n=8), PsA (UA>PsA, n=9), persistent UA (UA, n=16), established RA (n=12) and PsA (n=10), and healthy controls (n=6), were analyzed. Cell source and quantitative expression of GM-CSF and proteins associated with pro-inflammatory (GM-CSF-driven) and anti-inflammatory (M-CSF-driven) macrophage polarization (activin A, TNFα, MMP12, and CD209, respectively) were assessed in ST CD163+ macrophages by multicolor immunofluorescence. GM-CSF and activin A levels were also quantified in paired synovial fluid samples. CD163+ macrophage density was determined in all groups by immunofluorescence. Results: Synovial stromal cells (FAP+ CD90+ fibroblast, CD90+ endothelial cells) and CD163+ sublining macrophages were the sources of GM-CSF. ST CD163+ macrophages from all groups expressed pro-inflammatory polarization markers (activin A, TNFα, and MMP12). Expression of the M-CSF-dependent anti-inflammatory marker CD209 identified two macrophage subsets (CD163+ CD209high and CD163+ CD209low/-). CD209+ macrophages were more abundant in ST from healthy controls and PsA patients, although both macrophage subtypes showed similar levels of pro-inflammatory markers in all groups. In paired synovial fluid samples, activin A was detected in all patients, with higher levels in UA>RA and RA, while GM-CSF was infrequently detected. ST CD163+ macrophage density was comparable between UA>RA and UA>PsA patients, but significantly higher than in persistent UA. Conclusions: GM-CSF is highly expressed by sublining CD90+ FAP+ synovial fibroblasts, CD90+ activated endothelium and CD163+ macrophages in different types of arthritis. The polarization state of ST macrophages was similar in all UA and established arthritis groups, with a predominance of pro-inflammatory GM-CSF-associated markers. CD163+ macrophage density was significantly higher in the UA phases of RA and PsA compared with persistent UA. Taken together, our findings support the idea that GM-CSF is a strong driver of macrophage polarization and a potential therapeutic target not only in RA but also in PsA and all types of UA.
Background and Aims: GM-CSF-dependent macrophage polarization has been demonstrated in rheumatoid arthritis (RA). Our aim was to seek diagnostic/prognostic biomarkers for undifferentiated arthritis (UA) by analyzing GM-CSF expression and source, macrophage polarization and density in joints of patients with UA evolving to RA or PsA compared with established RA or PsA, respectively. Methods: Synovial tissue (ST) from patients with UA evolving to RA (UA>RA, n=8), PsA (UA>PsA, n=9), persistent UA (UA, n=16), established RA (n=12) and PsA (n=10), and healthy controls (n=6), were analyzed. Cell source and quantitative expression of GM-CSF and proteins associated with pro-inflammatory (GM-CSF-driven) and anti-inflammatory (M-CSF-driven) macrophage polarization (activin A, TNFα, MMP12, and CD209, respectively) were assessed in ST CD163+ macrophages by multicolor immunofluorescence. GM-CSF and activin A levels were also quantified in paired synovial fluid samples. CD163+ macrophage density was determined in all groups by immunofluorescence. Results:Synovial stromal cells (FAP+ CD90+ fibroblast, CD90+ endothelial cells) and CD163+ sublining macrophages were the sources of GM-CSF. ST CD163+ macrophages from all groups expressed pro-inflammatory polarization markers (activin A, TNFα, and MMP12). Expression of the M-CSF-dependent anti-inflammatory marker CD209 identified two macrophage subsets (CD163+ CD209high and CD163+ CD209low/-). CD209+ macrophages were more abundant in ST from healthy controls and PsA patients, although both macrophage subtypes showed similar levels of pro-inflammatory markers in all groups. In paired synovial fluid samples, activin A was detected in all patients, with higher levels in UA>RA and RA, while GM-CSF was infrequently detected. ST CD163+ macrophage density was comparable between UA>RA and UA>PsA patients, but significantly higher than in persistent UA. Conclusions: GM-CSF is highly expressed by sublining CD90+ FAP+ synovial fibroblasts, CD90+ activated endothelium and CD163+ macrophages in different types of arthritis. The polarization state of ST macrophages was similar in all UA and established arthritis groups, with a predominance of pro-inflammatory GM-CSF-associated markers. CD163+ macrophage density was significantly higher in the UA phases of RA and PsA compared with persistent UA. Taken together, our findings support the idea that GM-CSF is a strong driver of macrophage polarization and a potential therapeutic target not only in RA but also in PsA and all types of UA.
Authors: David Kuo; Jennifer Ding; Ian S Cohn; Fan Zhang; Kevin Wei; Deepak A Rao; Cristina Rozo; Upneet K Sokhi; Sara Shanaj; David J Oliver; Adriana P Echeverria; Edward F DiCarlo; Michael B Brenner; Vivian P Bykerk; Susan M Goodman; Soumya Raychaudhuri; Gunnar Rätsch; Lionel B Ivashkiv; Laura T Donlin Journal: Sci Transl Med Date: 2019-05-08 Impact factor: 17.956
Authors: Andrew D Cook; Jarrad Pobjoy; Shannon Sarros; Stefan Steidl; Manuela Dürr; Derek C Lacey; John A Hamilton Journal: Ann Rheum Dis Date: 2012-07-24 Impact factor: 19.103
Authors: Christopher T Ritchlin; Sally A Haas-Smith; Ping Li; David G Hicks; Edward M Schwarz Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808
Authors: Carmen A Ambarus; Troy Noordenbos; Maria J H de Hair; Paul P Tak; Dominique L P Baeten Journal: Arthritis Res Ther Date: 2012-04-11 Impact factor: 5.156
Authors: Sarah M Wade; Mary Canavan; Trudy McGarry; Candice Low; Siobhan C Wade; Ronan H Mullan; Douglas J Veale; Ursula Fearon Journal: Ann Rheum Dis Date: 2019-01-09 Impact factor: 19.103
Authors: Dominique Baeten; Elli Kruithof; Leen De Rycke; Anemieke M Boots; Herman Mielants; Eric M Veys; Filip De Keyser Journal: Arthritis Res Ther Date: 2005-01-21 Impact factor: 5.156
Authors: D E A Greven; E S Cohen; D M Gerlag; J Campbell; J Woods; N Davis; A van Nieuwenhuijze; A Lewis; S Heasmen; M McCourt; D Corkill; A Dodd; J Elvin; G Statache; I P Wicks; I K Anderson; A Nash; M A Sleeman; P P Tak Journal: Ann Rheum Dis Date: 2014-06-16 Impact factor: 19.103
Authors: Maarten M Steinz; Aiarpi Ezdoglian; Fatemeh Khodadust; Carla F M Molthoff; Madduri Srinivasarao; Philip S Low; Gerben J C Zwezerijnen; Maqsood Yaqub; Wissam Beaino; Albert D Windhorst; Sander W Tas; Gerrit Jansen; Conny J van der Laken Journal: Front Immunol Date: 2022-02-02 Impact factor: 7.561
Authors: Kimberly Pistorius; Lucy Ly; Patricia R Souza; Esteban A Gomez; Duco S Koenis; Ana R Rodriguez; Julie Foster; Jane Sosabowski; Mark Hopkinson; Vinothini Rajeeve; Bernd W Spur; Andrew Pitsillides; Costantino Pitzalis; Jesmond Dalli Journal: EBioMedicine Date: 2022-04-14 Impact factor: 11.205